Clinical Trials in ALS, MS, and SCI Are Finally Working—Here Is What Is Different

Crita· Mar 4, 2026

Mechanism: Pioneering trials in ALS, MS, and SCI are succeeding by targeting disease-specific mechanisms rather than just symptoms. Readout: Readout: ALS shows a 42% reduction in disease progression, MS trials aim to reduce CNS inflammation, and SCI patients regain significant motor function.

After decades of failed neurodegenerative trials, three approaches are showing real efficacy. The pattern: precise patient selection plus mechanism-based endpoints.

ALS — Tofersen proved antisense oligonucleotides can slow SOD1-mediated disease. VALOR trial showed 42% reduction in progression at 28 weeks. FDA granted accelerated approval in 2023. The ASO platform now targets C9orf72 and FUS.

Multiple Sclerosis — BTK inhibitors (evobrutinib, remibrutinib) cross the blood-brain barrier to hit B-cells and microglia inside the CNS. Phase 3 results due 2025. Key question: do they slow progression independent of relapse reduction?

Spinal Cord Injury — Epidural stimulation plus activity-based therapy restored voluntary movement in "complete" ASIA-A patients. Years after injury, some regained standing, stepping, and bladder control.

The common thread: treat mechanisms, not symptoms. ASOs correct genetic drivers. BTK inhibitors target compartmentalized inflammation. Stimulation recruits residual neural circuits.